Lisocabtagene maraleucel improves survival for relapsed or refractory large B-cell lymphoma
1. Median event-free survival in the liso-cel group was significantly greater than in the standard-of-care group (10.1 months vs. 2.3 ...
Tag: Diffuse large B-cell lymphoma (DLBCL)
Epcoritamab shows promising response rates seen in relapsed or refractory non-Hodgkin lymphoma
1. Full-dose regimens of 48-60 mg achieved clinically significant response rates varying from 68-100%. 2. No dose-limiting toxic effects were ...
#VisualAbstract: Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
1. Polatuzumab vedotin in combination with bendamustine and rituximab yielded higher complete response rates than bendamustine and rituximab alone. Evidence ...
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
1. Polatuzumab vedotin in combination with bendamustine and rituximab yielded higher complete response rates than bendamustine and rituximab alone. Evidence ...